
James Heyward

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7839497/publications.pdf Version: 2024-02-01



IAMES HEVWARD

#	Article	IF	CITATIONS
1	Telemedicine and Office-Based Care for Behavioral and Psychiatric Conditions During the COVID-19 Pandemic in the United States. Annals of Internal Medicine, 2021, 174, 428-430.	2.0	23
2	Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3969-3976.	2.0	28
3	Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Keynote and panel discussion on communicating heterogeneous treatment effects across populations. Pharmaceutical Statistics, 2021, 20, 965-978.	0.7	0
4	Ambulatory <scp>noninsulin</scp> treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. Diabetes, Obesity and Metabolism, 2021, 23, 1843-1850.	2.2	9
5	Primary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional survey. Drug and Alcohol Dependence, 2021, 225, 108811.	1.6	20
6	Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020. JAMA Network Open, 2021, 4, e2128782.	2.8	16
7	Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration. JAMA Internal Medicine, 2020, 180, 301.	2.6	25
8	Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018. Annals of Internal Medicine, 2020, 173, 956-963.	2.0	2
9	Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US. JAMA Network Open, 2020, 3, e2021476.	2.8	332
10	Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0234065.	1.1	59
11	Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program—Reply. JAMA Internal Medicine, 2020, 180, 916.	2.6	0
12	Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products. JAMA - Journal of the American Medical Association, 2019, 321, 676.	3.8	30
13	Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers. JAMA Network Open, 2018, 1, e183044.	2.8	98
14	Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers. JAMA Network Open, 2018, 1, e180235.	2.8	37
15	The Value of U.S. Pharmacopeial Standards: A Review of the Literature. Journal of Pharmaceutical Sciences, 2018, 107, 2611-2617.	1.6	7
16	Setting Priorities for Diabetic Retinopathy Clinical Research and Identifying Evidence Gaps. Ophthalmology Retina, 2017, 1, 94-102.	1.2	14
17	Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review. Systematic Reviews, 2015, 4, 143.	2.5	15